Myriad SWOT Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Myriad Bundle
Elevate Your Analysis with the Complete SWOT Report
Unpack Myriad’s competitive edge, vulnerabilities, and growth levers with our concise SWOT preview—then get the full, research-backed analysis to act with confidence. The complete report delivers detailed findings, strategic recommendations, and editable Word and Excel files for planning or pitching. Purchase now to access the investor-ready toolkit.
Strengths
Trusted brand in genetic testing
Myriad (NYSE:MYGN) has built a trusted oncology and women’s health brand over 30+ years, boosting clinician confidence and patient adoption. Decades of clinical use contribute to perceived reliability and support inclusion in clinical guidelines. Brand strength enhances payer negotiations and reduces customer acquisition costs in core segments.
Deep proprietary variant database
Myriad’s deep proprietary variant database improves interpretation accuracy and reporting speed by consolidating extensive curated evidence across genes, lowering VUS calls and reducing repeat testing. Superior call quality enhances clinical utility and provider satisfaction through clearer, actionable reports and faster turnaround. This accumulated data and clinician trust create a defensible moat that raises barriers for newer entrants.
Diversified portfolio across key indications
Myriad’s diversified portfolio across oncology, women’s health and pharmacogenomics smooths demand cycles, with FY2024 revenue of about $594 million reflecting broad-based income. Multiple revenue streams reduce dependence on any single test, lowering concentration risk. Cross-selling between divisions boosts account value and lifetime customer revenue. This mix enhances resilience amid policy changes or competitive pressure.
Established payer coverage and guidelines presence
Established payer coverage reduces patient out-of-pocket friction and boosts test volumes, with contracts spanning major commercial payers covering over 200 million U.S. lives, and inclusion in clinical guidelines standardizes ordering and drives steady referral patterns. Contracted rates with payers and health systems increase revenue visibility and reinforce partnerships with top IDNs.
- Lower OOP, higher volumes
- Guideline-driven ordering
- Contracted rates = revenue visibility
- Stronger HS/IDN relationships
Integrated lab operations and clinician support
Integrated end-to-end lab operations let Myriad control quality and turnaround, while embedded genetic counseling and provider education drive appropriate test utilization and referral growth; seamless ordering and reporting tools streamline clinician workflow and boost retention.
- Quality control: centralized lab processes
- Utilization: genetic counseling embedded
- Workflow: seamless ordering/reporting
- Business impact: higher retention and referrals
Clinically trusted genomics with $594M rev, covers ~200M
Myriad leverages 30+ years of clinical trust, driving clinician adoption and guideline inclusion. FY2024 revenue was about $594 million, reflecting diversified oncology, women’s health, and pharmacogenomics streams. Payer contracts cover ~200 million U.S. lives, improving access and volume. Proprietary variant database and in-house labs lower VUS rates and speed turnaround, strengthening provider loyalty.
| Metric | Value |
|---|---|
| FY2024 revenue | $594M |
| Payer-covered lives | ~200M |
| Market tenure | 30+ years |
What is included in the product
Detailed Word Document
Delivers a strategic overview of Myriad’s internal and external business factors, outlining strengths, weaknesses, opportunities, and threats to assess competitive position and inform strategic decisions about growth and risk management.
Customizable Excel Spreadsheet
Myriad's SWOT Analysis delivers a compact, visual overview that quickly aligns teams, clarifies priorities, and reduces time spent on strategic debates, easing decision-making and coordination across units.
Weaknesses
Exposure to reimbursement variability
Coverage policy and coding changes materially affect Myriad’s test pricing and volumes, with shifting payer policies driving demand volatility. Prior authorization requirements slow clinical adoption and create access bottlenecks. Higher claim denials raise administrative costs and elongate cash conversion cycles. These factors keep margin predictability constrained.
Legacy patent and litigation overhang
Historic IP battles culminated in the 2013 Supreme Court decision (AMP v. Myriad) that invalidated key gene patents, diluting Myriad’s prior exclusivity. Competitors rapidly expanded BRCA and hereditary cancer panels once barriers fell, compressing pricing and market share. Ongoing legal costs and potential follow‑on disputes remain a recurring drain, and investors often price this litigation overhang into Myriad’s valuation.
Profitability sensitivity to volume mix
Myriad’s high fixed lab and staffing costs mean profitability hinges on volume scale, so downward mix shifts toward lower-ASP tests can materially compress margins. Volatile case mix has repeatedly pressured EBITDA in prior quarters, heightening reliance on steady demand and long-term test adoption rates. This sensitivity limits earnings leverage during reimbursement or demand softness.
Complex regulatory compliance footprint
Operating under CLIA and CAP while FDA continues to consider expanded LDT oversight increases costs through enhanced documentation, validation and QA; these processes are resource-intensive and raise per-test operating expenses. Multi-state and international regulatory variations complicate rollouts and revenue recognition, and any compliance lapse could trigger stoppages, fines or lab shutdowns that materially disrupt operations.
- Regulatory layers: CLIA/CAP plus potential FDA LDT changes
- Resource burden: extensive documentation, validation, QA
- Geographic complexity: divergent state and international rules
- Operational risk: lapses can halt lab services or invite penalties
Data integration and interoperability gaps
Data integration and interoperability gaps fragment EHR connectivity, hindering order placement and timely result delivery; 96% of US hospitals use certified EHRs (ONC 2022) yet exchange remains inconsistent. Limited workflow integration reduces provider stickiness and increases churn. Manual processes raise error risk and overhead, slowing scale-up in large health systems.
- Fragmented EHR connectivity — delays in orders/results
- Limited workflow integration — lower provider retention
- Manual processes — higher error rate and overhead
- Scale barrier — harder rollout across large systems
Prior auths, payer shifts and 2013 IP ruling pressure lab margins 96% EHRs
Payer policy shifts and prior authorization drive demand volatility and higher denials, constraining margin predictability. Loss of patent exclusivity after AMP v. Myriad (2013) enabled rapid competitor entry and pricing pressure. High fixed lab costs and regulatory/LDT uncertainty make profitability volume‑sensitive; EHR fragmentation (96% hospitals use certified EHRs, ONC 2022) limits workflow stickiness.
| Issue | Relevant fact |
|---|---|
| EHR reach | 96% hospitals use certified EHRs (ONC 2022) |
| IP watershed | AMP v. Myriad, 2013 |
| Volume risk | High fixed lab/staff costs |
Same Document Delivered
Myriad SWOT Analysis
This is the actual Myriad SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the complete, editable version. The file shown is the real analysis you'll download post-purchase and is ready to use immediately after checkout.
Opportunities
Broader hereditary cancer and women’s health adoption
Expanding clinical guidelines and risk-based screening — with hereditary testing uptake still under 25% among eligible patients — can materially lift test penetration and revenue. Earlier detection initiatives prioritize genetic risk assessment, aligning with payer coverage trends that increase reimbursement. Standardized OB/GYN and oncology ordering pathways create predictable workflows and drive recurring referral streams, supporting steady downstream volume growth.
Growth in pharmacogenomics for mental health
Rising interest in precision psychiatry supports PGx testing—GUIDED trial evidence showed response rates ~44% vs 30% with combinatorial PGx-guided prescribing, strengthening clinical adoption. Payers increasingly recognize cost offsets from reduced trial-and-error prescribing, prompting expanding private payer coverage in 2023–2025. Telepsychiatry expansion provides scalable channels and accumulating outcomes data can unlock broader reimbursement.
Population genomics and health system partnerships
Large cohort programs (UK Biobank ~500,000 participants; All of Us >500,000) enable upfront risk stratification at scale, while embedding testing in care pathways drives utilization and earlier referrals. Data-sharing pacts bolster variant knowledgebases (ClinVar >1.5M entries), and health-system partnerships often convert into multi-year revenue anchors for diagnostics providers.
AI/ML to improve interpretation and throughput
- 30–50% TAT reduction
- 15–25% lower VUS rates
- ~20% higher physician adherence
- Margin expansion (several ppt)
International expansion and new indications
Selective international entries can diversify Myriad’s revenue base; Myriad reported roughly $664M in 2024, so targeting high-margin markets could reduce U.S. concentration risk and lift top-line growth.
Localization to regional guidelines boosts payer acceptance; expanding into cardiometabolic and rare-disease testing taps a global genetic-testing market near $22B in 2024 with ~11% CAGR, while partnerships cut go-to-market costs and regulatory risk.
- Revenue tag: Myriad ~ $664M (2024)
- Market tag: genetic testing ~$22B (2024), ~11% CAGR
- Therapy tag: cardiometabolic/rare disease expand TAM
- Risk-mitigation tag: partnerships lower GTM/regulatory risk
Hereditary testing uptake 25%; AI/ML cuts TAT 30–50%
Hereditary testing uptake <25% presents material upside; payer coverage expanded 2023–25 and precision psychiatry PGx adoption rises. AI/ML can cut TAT 30–50%, lower VUS 15–25% and lift physician adherence ~20%, improving margins. International expansion into high-margin markets and cardiometabolic/rare-disease tests taps a ~$22B genetic-testing market (2024).
| Tag | Value |
|---|---|
| Myriad rev (2024) | $664M |
| Market (2024) | $22B; ~11% CAGR |
| TAT | 30–50%↓ |
| VUS | 15–25%↓ |
Threats
Intense competition and price pressure
Multiple diagnostics players crowd oncology and women’s health—competitors such as Natera, Guardant Health, Roche/Foundation Medicine, Invitae and LabCorp intensify rivalry in a molecular diagnostics market valued at roughly $10–11B in 2023. Aggressive pricing and bundled offerings compress average selling prices, while some hospital systems increasingly in‑source testing; differentiation must outpace commoditization to protect margins.
Evolving FDA oversight of LDTs
Stricter FDA oversight of LDTs—an active rulemaking topic through July 2025—could raise compliance costs and slow product launches, potentially delaying revenue recognition by months. Legacy assays may require additional validation and documentation, increasing per-test costs and operational burden. Smaller rivals or in-house hospital labs may adapt faster or pursue alternative pathways, altering competitive dynamics.
Data privacy and cybersecurity risks
Genomic data is highly sensitive and attractive to attackers; a breach would erode patient trust and trigger heavy penalties—GDPR fines up to €20m or 4% global turnover and HIPAA penalties up to $2.5m per violation category. Healthcare breach average cost was $10.93m in IBM’s 2024 report, making ongoing security investments—often millions annually—both essential and costly.
Macroeconomic and payer budget constraints
Tight payer and public budgets in 2024–25 intensify utilization management and prior-authorization hurdles for Myriad, driving slower test ordering as employers and plans push lower-cost diagnostic alternatives.
Patients increasingly defer non-urgent genetic testing amid cost concerns; softer volume amplifies Myriad’s fixed-cost burden and squeezes margins.
- Heightened PA and UM
- Shift to lower-cost substitutes
- Patient deferrals reduce volume
- Fixed-cost leverage worsens margins
Technology shifts and obsolescence
Rapid advances in sequencing and liquid biopsy—markets expanding at roughly 15–20% CAGR—can reset clinical standards, while new biomarkers and multi-cancer early detection tests redirect demand away from Myriad’s legacy assays. Slow innovation risks clinical irrelevance and payer delisting; capital expenditures may need to rise materially to upgrade platforms and validate MCED panels.
- Threat: market CAGR ~15–20%
- Threat: MCED/biomarker shifts
- Threat: clinical relevance loss if innovation lags
- Threat: rising capex for platform upgrades
Market squeeze: $10-11B sector, 15-20% tech CAGR
Intense competition (market ~$10–11B in 2023) and 15–20% CAGR in sequencing/liquid biopsy threaten price compression and volume loss. Tight payer controls and patient deferrals cut utilization; legacy assays risk payer delisting without rapid innovation. Regulatory LDT shifts through 2025 raise compliance costs; cyber breaches (avg cost $10.93m in 2024) pose material financial and reputational risk.
| Threat | Key data | Impact |
|---|---|---|
| Market size | $10–11B (2023) | Competitive intensity |
| Tech CAGR | 15–20% (2024–25) | Innovation pressure |
| Cyber breach cost | $10.93M (2024) | Financial/legal |